Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

A Systematic Review on the Causative Medicines for Stevens-Johnson Syndrome

스티븐스-존슨증후군을 유발하는 주요 의약품별 위험도에 대한 체계적 문헌고찰

  • Received : 2013.03.05
  • Accepted : 2013.11.01
  • Published : 2013.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are immune-complex-mediated hypersensitivity reactions that predominantly involve skin and mucous membranes. Despite the low incidence, both are considered medical emergencies as the mortality rate has been estimated at 30-50%. Although as many as half of cases are idiopathic, several drugs have been implicated as main cause of SJS/TEN. This review therefore aimed to identify drugs that were potentially associated with SJS/TEN and compare the relative risk of the medications. Method: A comprehensive search was performed using MEDLINE, EMBASE and 5 Korean databases. We defined study drugs as non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, antiepileptics, and allopurinol. Only epidemiologic studies investigating associations between the above drugs and drug-induced SJS/TEN were included. Two reviewers independently selected and evaluated candidate papers and extracted odds ratios or incidence rates. Meta-analysis was performed only for drugs that were reported from 4 or more studies. Results: We found 8 case-control studies, 3 cohort studies and 1 RCT. The ranges of adjusted ORs were 0.6-34.0 for NSAIDs, 1.6-302.0 for antiepileptics, 0.3-10.0 for antibiotics and 1.0-187.0 for allopurinol. The drug with the highest incidence of SJS/TEN was carbamazepine (40 persons/1,000 DDD). Conclusion: Finally, the risk was highest in first 8 weeks after onset of treatment in all drugs.

Keywords

References

  1. Papay J, Yuen N, Powell G, et al. Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications. Pharmacoepidemiology and drug safety 2012; 21: 289-96. https://doi.org/10.1002/pds.2276
  2. Tan SK, Tay YK. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Acta Derm Venereol 2012; 92: 62-6. https://doi.org/10.2340/00015555-1169
  3. Mockenhaupt M. Severe cutaneous adverse reactions, In: Burgdorf WHC, Plewig G, Wolff HH, Landthaler M, eds. Braun-Falco's Dermatology, 3rd ed. Heidelberg, Germany: Springer Medizin Verlag, 2008: 473-83.
  4. Auquier DA, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol 2002; 138: 1019-24.
  5. 주민우(2012 May 20). "日, 감기약 등 먹고 131명 사망: 스티븐스-존슨증후군 보고". 헬스코리아뉴스. Available from: http://www.hkn24.com/news/articleView.html?idxno=99236 [accessed 2013 Feb. 13].
  6. 윤주애(2012 May 2). "치명적 스티븐존슨증후군 매년 1천명 발생". 마이경제신문. Available from: http://www.onsumernews.co.kr/news/view.html?gid=main&bid= news&pid=309985 [accessed 2013 Feb. 13].
  7. Tartarone A, Lerose R. Stevens-Johnson syndrome and toxic epidermal necrolysis: what do we know? Ther Drug Monit 2010; 32(6): 669-72. https://doi.org/10.1097/FTD.0b013e3181f2f24f
  8. Barvaliya M, Sanmukhani J, Patel T et al. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. J Postgrad Med 2011; 57: 115-9. https://doi.org/10.4103/0022-3859.81865
  9. http://clinicalevidence.bmj.com/x/set/static/ebm/learn/665076.html [accessed 2013 Feb. 13].
  10. Scottish Intercollegiate Guidelines Network. Search filters. Available from: http://www.sign.ac.uk/methodology/filters.html [accessed 2013 Feb. 13].
  11. Korean medical library engine. Available from: http://www.kmle.co.kr/ [accessed 2013 Feb. 13].
  12. Mockenhaupt M, Kelly JP, Kaufman D, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol 2003; 30(10): 2234-40.
  13. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa scale(NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from : http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp [accessed 2013 Feb. 13].
  14. West SL, Gartlehner G, Mansfield AJ, et al. Comparative Effectiveness Review Methods: Clinical Heterogeneity. Agency for Healthcare Research and Quality; September 2010. Methods Research Paper. AHRQ Publication No. 10-EHC070-EF. Available from: http://effectivehealthcare.ahrq.gov/ [accessed 2013 Oct. 11].
  15. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58(1): 25-32. https://doi.org/10.1016/j.jaad.2007.08.036
  16. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128(1): 35-44. https://doi.org/10.1038/sj.jid.5701033
  17. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333(24): 1600-7. https://doi.org/10.1056/NEJM199512143332404
  18. Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case control study. Lancet 1999; 26: 2190-4.
  19. Kaufman DW, Kelly JP. Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Clin Pharmacol 2001; 51(2): 174-6. https://doi.org/10.1111/j.1365-2125.2001.01323.x
  20. Egger M, Davey Smith G, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34. https://doi.org/10.1136/bmj.315.7109.629
  21. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001; 20: 641-54. https://doi.org/10.1002/sim.698
  22. Lin MS, Dai YS, Pwu RF, et al. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study, Intern Med J 2005; 35(3): 188-90. https://doi.org/10.1111/j.1445-5994.2005.00790.x
  23. Gau SS, Chao PF, Lin YJ, et al. The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study, J Clin Psychopharmacol 2008; 28(5): 509-17. https://doi.org/10.1097/JCP.0b013e3181845610
  24. Campos-Fernndez Mdel M, Ponce-De-Len-Rosales S, Archer-Dubon C, et al. Incidence and risk factors for cutaneous adverse drug reactions in an intensive care unit. Rev Invest Clin, 2005; 57(6): 770-4.
  25. Hernndez-Salazar A, Rosales SP, Rangel-Frausto S, et al. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res 2006; 37(7): 899-902. https://doi.org/10.1016/j.arcmed.2006.03.010
  26. Judlin P, Liao Q, Liu Z, et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG, 2010; 117(12): 1475-84. https://doi.org/10.1111/j.1471-0528.2010.02687.x
  27. Ryu JH, Kyoung EJ, Lee HY, et al. Comparative analysis of drug information resources for dose adjustment in terms of renal and hepatic function. Kor J Clin Pharm 2012; 22(3): 220-7.
  28. Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between $HLA-B^*5801$ and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19(9): 704-9. https://doi.org/10.1097/FPC.0b013e328330a3b8
  29. Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al. Association between $HLA-B^*1502$ and carbamazepineinduced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010; 51(5): 926-30. https://doi.org/10.1111/j.1528-1167.2010.02533.x
  30. Kim EJ, Lee KE, Gwak HS. Analysis of ethnic differences in physician's desk reference. Kor J Clin Pharm 2013; 23(2): 123-8.
  31. Ferrell PB, McLeod HL. Carbamazepine, $HLA-B^*1502$ and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9: 1543-6. https://doi.org/10.2217/14622416.9.10.1543
  32. Kim SH, Lee KW, Song WJ, et al. Carbamazepineinduced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res 2011; 97(1-2): 190-7. https://doi.org/10.1016/j.eplepsyres.2011.08.010
  33. Kim HI, Kim SW, Park GY, et al. Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients. Korean J Intern Med 2012; 27(2): 203-10. https://doi.org/10.3904/kjim.2012.27.2.203
  34. PMDA office of safety. (2012 Apr.). PMDA Request for Proper Use of Drugs. Available from: http://www.pmda.go.jp/english/service/pdf/request/No9.pdf [accessed 2013 Feb. 13].